8-KEarnings & ResultsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Financial Results (Jul 28, 2021)

Filed July 28, 2021For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC) filed an 8-K on July 28, 2021, to provide updated financial information related to its prospectus and a preliminary range of financial results for the six months ended June 30, 2021. The company is preparing to list on the STAR Market in China and has provided R&D expenses by key products and other projects for 2018-2020, prepared under PRC GAAP. Investors should note that the preliminary financial results for H1 2021 have not been audited and are subject to change. The filing also includes forward-looking statements concerning the proposed RMB share issuance, highlighting that this offering is contingent on market conditions and regulatory approvals, and there is no certainty it will proceed. Shareholders are advised to exercise caution.

Key Highlights

  • 1BeOne Medicines Ltd. provided preliminary financial results for the six months ended June 30, 2021, which include total revenue and net loss attributable to the Company.
  • 2These preliminary results were prepared in accordance with PRC GAAP and have not been audited or reviewed by independent accountants.
  • 3The company also disclosed detailed R&D expenses allocated by key products and other projects for the years 2018, 2019, and 2020, prepared under PRC GAAP.
  • 4The filing discusses a proposed issuance of RMB Shares to be listed on the STAR Market, subject to market conditions and necessary regulatory approvals.
  • 5There is a risk that the proposed RMB share issuance may not materialize or could be delayed.
  • 6The company emphasizes that the information provided is for informational purposes and does not constitute an offer to buy or sell securities.
  • 7Investors are cautioned about the uncertainty of the RMB share issuance and advised to exercise caution when dealing with the company's securities.

Frequently Asked Questions

The preliminary financial results provide investors with an early look at the company's performance in the first half of 2021, including total revenue and net loss. However, it is crucial to note that these figures are unaudited and subject to change following further review.

The proposed issuance of RMB Shares for listing on the STAR Market is conditional upon favorable market conditions and obtaining the necessary regulatory approvals. The company explicitly states that there is no assurance that the offering will proceed or when it might occur, advising investors to exercise caution.

The financial information disclosed in this filing, including the R&D expenses for 2018-2020 and the preliminary results for H1 2021, is prepared in accordance with PRC GAAP. Corresponding information prepared under US GAAP is available in Exhibit 99.1.

The prospectus mentioned in the filing is available in Chinese only on the website of the Shanghai Stock Exchange (www.sse.com.cn). The information on the exchange's website is not considered part of this 8-K filing.